Show simple item record

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

dc.contributor.author Bostwick, AD
dc.contributor.author Hanks, Brent A
dc.contributor.author Salama, April KS
dc.coverage.spatial England
dc.date.accessioned 2016-03-01T14:11:56Z
dc.date.issued 2015
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/25992290
dc.identifier 64
dc.identifier.uri http://hdl.handle.net/10161/11661
dc.description.abstract While blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) T cell regulatory receptor has become a commonly utilized strategy in the management of advanced melanoma, many questions remain regarding the use of this agent in patient populations with autoimmune disease. We present a case involving the treatment of a patient with stage IV melanoma and ulcerative colitis (UC) with anti-CTLA-4 antibody immunotherapy. Upon initial treatment, the patient developed grade III colitis requiring tumor necrosis factor-alpha (TNF-α) blocking antibody therapy, however re-treatment with anti-CTLA-4 antibody following a total colectomy resulted in a rapid complete response accompanied by the development of a tracheobronchitis, a previously described extra-intestinal manifestation of UC. This case contributes to the evolving literature on the use of checkpoint inhibitors in patients also suffering from autoimmune disease, supports future clinical trials investigating the use of these agents in patients with autoimmune diseases, and suggests that an understanding of the specific molecular pathways involved in a patient's autoimmune pathology may provide insight into the development of more effective novel combinatorial immunotherapeutic strategies.
dc.language eng
dc.relation.ispartof J Immunother Cancer
dc.relation.isversionof 10.1186/s40425-015-0064-2
dc.subject Advanced melanoma
dc.subject Autoimmunity
dc.subject Ipilimumab
dc.subject Ulcerative colitis
dc.title Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/25992290
pubs.begin-page 19
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group School of Medicine
pubs.publication-status Published online
pubs.volume 3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record